<DOC>
	<DOCNO>NCT01624467</DOCNO>
	<brief_summary>The purpose study determine whether treatment necitumumab monotherapy affect QT/QTc interval among participant advance solid tumor refractory standard treatment standard treatment available .</brief_summary>
	<brief_title>A Study Necitumumab Monotherapy QT/QTc Interval Patient With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have document advanced metastatic malignant solid tumor ( except colorectal tumor KRAS mutation ) respond standard therapy standard therapy available May measurable nonmeasurable disease Have resolution Grade 0 1 National Cancer Institute Common Terminology Criteria Adverse Events , Version 4.0 ( NCICTCAE 4.0 ) clinically significant toxic effect prior chemotherapy , surgery , radiotherapy , hormonal therapy Have Eastern Cooperative Oncology Group performance status ( ECOG PS ) score 0 1 Have adequate hepatic , renal hematologic function Have potassium , magnesium , calcium within normal limit Subjects , female , surgically sterile , postmenopausal , compliant highly effective contraceptive method 6 month treatment period . If male , participant surgically sterile compliant highly effective contraceptive regimen 6 month treatment period Female subject childbearing potential must negative serum pregnancy test within 7 day prior randomization Are currently enrol , discontinue clinical trial involve anticancer investigational product , concurrently enrol type medical research Had therapeutic radiotherapy within 14 day prior first dose study therapy Have receive necitumumab monoclonal antibody ( mAb ) target EGFR ( epidermal growth factor receptor ) recent prior treatment Have document and/or symptomatic brain leptomeningeal metastasis Have clinically relevant abnormality ECG , prevent accurate measurement QT interval Have current clinicallyrelevant coronary artery disease uncontrolled congestive heart failure Have medically uncontrolled angina pectoris , experience myocardial infarction within 6 month prior first dose study therapy Have implantable pacemaker automatic implantable cardioverter defibrillator Have receive sotalol within 10 day prior first dose study therapy Have history risk factor ventricular tachycardia Torsades de pointes , history fainting , unexplained loss consciousness , convulsion Have history heart failure , congestive heart failure , myocardial infarction , cardiomyopathy , hypokalemia , hypoglycemia , hypomagnesia Have evidence conduction abnormality ( eg , increased QRS complex ) Have congenital long QT syndrome Have prolong QTc interval mean pretreatment ECG Have heart rate &lt; 50 bpm &gt; 100 bpm rest Are use medication know prolong ECG QT interval , receive medication know prolong ECG QT interval within 14 day prior first dose study therapy Have know allergy / history hypersensitivity reaction treatment component , include ingredient use formulation necitumumab , know history severe ( Grade 34 ) hypersensitivity reaction monoclonal antibody Have ongoing active infection ( require treatment ) , include active tuberculosis know infection human immunodeficiency virus If female , pregnant breastfeeding Have history significant neurological psychiatric disorder , include dementia , seizure , bipolar disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>